
| Lipo-6 Rapid Weight Loss Aid | ||
| DMAE Bitartrate | 150 mg | † |
| Caffeine Anhydrous | 135 mg | † |
| Theacrine | 100 mg | † |
| N-Acetyl-L-Tyrosine | 100 mg | † |
| Dicaffeine Malate | 100 mg | † |
| Ginger root CO2 extract | 20 mg | † |
| Rauwolscine | 1 mg | † |
Other ingredients: Glycerin, purified Water, Hypromellose, FD&C Yellow 6, FD&C Red 40, FD&C Blue 1
% Daily Values for: Adults and children 4 or more years of age.
Where this label comes from
An original label of the NIH's Dietary Supplement Label Database, entered there on 31 August 2018, shown here as it was entered. The NIH's record
General information
- Product name
- Lipo6 Rx
- Brand
- Nutrex Research Clinical Edge
- Barcode (UPC)
- 8 57839 00630 3
- Net contents
- 60 Liqui-Cap(s)
- Market status
- Off market
- DSLD ID
- 176248
Classification
- Supplement form
- Capsule
- Product type
- Other Combinations
- Claim types on the label
- All Other, Structure/Function
- Intended for
- Adult (18 - 50 Years)
Label statements
Precautions: Children: Warning: Lipo-6 Rx is absolutely not for use by persons under the age of 18.
Precautions: Pregnant or Nursing or Prescription Medications: Do not use if pregnant or nursing.
Precautions: All Other: Do not consume this product with alcohol. Never exceed the maximum dosage.
Precautions: Pregnant or Nursing or Prescription Medications: Do not consume thyroid-boosting compounds for other sources, including but not limited to, coffee, tea, soda and other dietary supplements, nurtraceuticals or medications containing any stimulants whatsoever.
Formula: Contains: This product contains 221mg of caffeine per serving.
Precautions: All Other: This product contains 221mg of caffeine per serving. Do not use this product for longer than 60 days. Follow with a 15 day break.
Precautions: Pregnant or Nursing or Prescription Medications: Consult your physician prior to use if you are taking medication, including but not limited to, MAOI inhibitors, anti-depressants, aspirin, non-steroidal anti-inflammatory drugs or products containing phenylephrine, ephedrine, pseudoephedrine, phenylethylamine or other stimulants.
Precautions: All Other: Consult your physician prior to use if you have a medical condition, including but not limited to, heart, liver, kidney or thyroid disease, psychiatric disorders, difficulty urinating, diabetes, high blood pressure, cardiac arrhythmia, recurrent headaches, enlarged prostate or glaucoma. Discontinue use 2 weeks prior to surgery. Immediately discontinue if you experience rapid heartbeat, dizziness, severe headaches or shortness of breath. This product contains ingredients that may be banned by some sports organizations.
Precautions: Children: Keep out of reach of children.
Formula: Contains: With TeaCrine
FDA Statement of Identity: Dietary Supplement
Formula: Contains: Clinically-tested TeaCrine
Directions: Recommended Use: Take 1 liqui-cap in the morning and 1 liqui-cap in the afternoon. Take liqui-cap on an empty stomach. If you are sensitive, or do not know your tolerance for weight-loss supplements, consume food 15-30 minutes after ingestion. Due to the maximum potency do not take more than 1 liqui-cap per serving. Never take more than two liqui-caps in a 24 hour period. Do not take within 6 hours of sleep. Drink at least 6-8 glasses of water per day.
Precautions: All Other: Never take more than two liqui-caps in a 24 hour period. Do not take within 6 hours of sleep.
Brand information
Developed by & Manufactured Exclusively for:: Nutrex Research, Inc., Oviedo, FL, USA
More labels from Nutrex Research Clinical Edge
Labels only: each label is shown as printed on the bottle, with no grades, rankings or advice. A label in this database is not an endorsement of the product. Read the label on the bottle you buy: makers change their formulas. Reverse Age Lab is not affiliated with, or endorsed by, the National Institutes of Health or its Office of Dietary Supplements. The original labels come from the NIH’s public-domain data; the labels since are read by us. Search the Dietary Supplement Label Database.
